Nectar Lifesciences Limited — Important, 13-03-2025: Granting/withdrawal/surrender/cancellation/suspension of key licenses/ regulatory approvals

Nectar Lifesciences Ltd. has announced a board meeting to update shareholders on the recent inspection of its manufacturing facility by the European Directorate for the Quality of Medicines. The management acknowledges the seriousness of the situation and is committed to implementing necessary corrective actions. The EU market accounts for 2.7% of the company’s total API sales, highlighting its importance. This proactive approach to compliance and quality assurance reflects the company's strategy for sustainable growth. Investor sentiment may tilt positively, given the management's commitment to addressing regulatory concerns swiftly.